Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Fraunhofer Society has found minimal impact from lockdowns and the pandemic on the number of spinouts its institutes were able to generate last year.

The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.

Alexandria Real Estate Equities was among the participants as the drug discovery technology provider closed its series C round.

Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Lyell Immunopharma co-led a series A round for the gene therapy developer, which partially exploits UW research.

The Novo-backed musculoskeletal disease therapy developer's market capitalisation stood at $1.6bn as of close of trading yesterday.

Pfizer Ventures joined existing investors Ipsen and Leaps by Bayer and Pfizer Ventures in a round taking the oncology drug developer's overall funding to $174m.

The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.

The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.